Cargando…
Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field
The ability to create patient derived xenografts (PDXs) has evolved considerably from the breakthrough of the development of immune compromised mice. How researchers in drug discovery have utilized PDX of certain cancer types has also changed from traditionally selecting a few models to profile a dr...
Autor principal: | Williams, Juliet A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867567/ https://www.ncbi.nlm.nih.gov/pubmed/29498669 http://dx.doi.org/10.3390/jcm7030041 |
Ejemplares similares
-
PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery
por: Risbridger, Gail P, et al.
Publicado: (2020) -
Breast cancer PDxO cultures for drug discovery and functional precision oncology
por: Scherer, Sandra D., et al.
Publicado: (2023) -
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
por: Schmitt, Nanni, et al.
Publicado: (2021) -
Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery
por: Fu, Jingyu, et al.
Publicado: (2023) -
Evolving paradigms for natural-product drug discovery
por: Cordell, Geoffrey A
Publicado: (2022)